Background And Objectives: Although the recent approval of selumetinib is expected to transform the management of children with neurofibromatosis type 1 (NF1), particularly those with symptomatic and inoperable plexiform neurofibromas, no systematic review has summarized its efficacy and safety based on the latest studies. This study was conducted to systematically evaluate the efficacy and safety of selumetinib in children with NF1.
Methods: Original articles reporting the efficacy and safety of selumetinib in patients with NF1 were identified in PubMed and EMBASE up to January 28, 2021. The pooled objective response rates (ORRs) and disease control rates (DCRs) were calculated using the DerSimonian-Laird method based on random-effects modeling. The pooled proportion of adverse events (AEs) was also calculated. The quality of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation system.
Results: Five studies involving 126 patients were included in our analysis. The studies had a very low to moderate quality of the evidence. The pooled ORR was 73.8% (95% CI 57.3%-85.5%) and the DCR was 92.5% (95% CI 66.5%-98.7%). The 2 most common AEs were diarrhea, which had a pooled rate of 63.8% (95% CI 52.9%-73.4%), and an increase in creatine kinase levels, which had a pooled rate of 63.3% (95% CI 35.6%-84.3%).
Discussion: Our results indicate that selumetinib is an effective and safe treatment for pediatric patients with symptomatic, inoperable plexiform neurofibromas. Further larger-scale randomized controlled studies are needed to confirm the long-term outcome of patients treated with this drug.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/WNL.0000000000013296 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intralesional injection of CpG ODNs complexed with glatiramer acetate mitigates systemic cytokine toxicities and synergistically advances checkpoint blockade efficacy.
Drug Deliv Transl Res
January 2025
Kinimmune, Inc. St. Louis, 63141, Missouri, USA.
PD-L1/PD-1 checkpoint inhibitors (CPIs) are mainstream agents for cancer immunotherapy, but the prognosis is unsatisfactory in solid tumor patients lacking preexisting T-cell reactivity. Adjunct therapy strategies including the intratumoral administration of immunostimulants aim to address this limitation. CpG oligodeoxynucleotides (ODNs), TLR9 agonists that can potentiate adaptive immunity, have been widely investigated to tackle PD-L1/PD-1 resistance, but clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure.
View Article and Find Full Text PDFOral and topical spironolactone in acne treatment: A meta-analysis of effectiveness and safety.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Faculty of Medicine, Cairo University, Cairo, Egypt.
Acne vulgaris (AV) is a common chronic inflammatory skin disorder that commonly lasts from adolescence to adulthood and has serious social and psychological consequences. Current treatments typically use antibacterial drugs, which contributes to the rise in antibacterial drug resistance. Spironolactone, a potassium-sparing diuretic with anti-androgen effects, has been used off-label to treat acne by lowering sebum production.
View Article and Find Full Text PDFReconstruction of vibration noise in plate structures based on Data-Physics driven model and transfer learning.
J Acoust Soc Am
January 2025
Urban Construction Center of Lucheng District of Wenzhou, Wenzhou, 325000, China.
The identification of vibration and reconstruction of sound fields of plate structures are important for understanding the vibroacoustic characteristics of complex structures. This paper presents a data-physics driven (DPD) model integrated with transfer learning (DPDT) for high-precision identification and reconstruction of vibration and noise radiation of plate structures. The model combines the Kirchhoff-Helmholtz integral equation with convolutional neural networks, leveraging physical information to reduce the need for extensive data.
View Article and Find Full Text PDFFeasibility, Safety, and Impact of Awake Resection for Recurrent Insular Diffuse Gliomas in Adults.
Neurosurgery
January 2025
Service de Neurochirurgie, GHU-Paris Psychiatrie et Neurosciences, Paris, France.
Background And Objectives: The risk-to-benefit ratio of transopercular awake resection for recurrent insular diffuse gliomas is poorly studied. We assessed feasibility, safety, and efficacy of awake surgical resection of recurrent insular diffuse gliomas in patients with previous treatments (resection and/or radiotherapy and/or chemotherapy and/or combination).
Methods: Observational, retrospective, single-institution cohort analysis (2010-2023) of 123 consecutive adult patients operated on for an insular diffuse glioma (2021 World Health Organization classification) under awake conditions.
Body Mass Index Did Not Impact Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE UC Clinical Program.
Am J Gastroenterol
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Objective: High body mass index (BMI) may reduce ulcerative colitis (UC) treatment efficacy. Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active UC. This post hoc analysis assessed treatment outcomes according to BMI in ELEVATE UC 52 and ELEVATE UC 12.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!